Shares of Cybin Inc. (OTCMKTS:CYBN – Get Free Report) fell 4.3% on Wednesday . The company traded as low as $10.20 and last traded at $10.25. 204,600 shares were traded during mid-day trading, an increase of 10% from the average session volume of 186,805 shares. The stock had previously closed at $10.71.
Cybin Stock Performance
The company has a market cap of $204.92 million, a PE ratio of -1.54 and a beta of 0.38. The firm’s 50 day moving average is $10.19 and its 200-day moving average is $3.74.
About Cybin
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Recommended Stories
- Five stocks we like better than Cybin
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- ETF Screener: Uses and Step-by-Step Guide
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Want to Profit on the Downtrend? Downtrends, Explained.
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
